Abstract
BECAUSE of lacking fibrin selectivity two chain urokinase-type plasminogen activator(tcu-PA),which has been used as the clinical thrombolytic agent,may lead to bleeding by a remarkabledepletion of fibrinogen in plasma when injected in large doses,thus its clinical application islimited.Single chain urokinase-type plasminogen activator(scu-PA)is the precursor of tcu-
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
